EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

PDL-1 in non-small cell lung cancer (NSCLC): Association with molecular alterations and clinical outcome

Khalid Abdul Mannan, Daphne Fonseca, Sahithi S Arya iD, Kunteepuram Vaishnavi, Suseela Kodandapani, Senthil J Rajappa

Indian Journal of Cancer · 2025

DOI: 10.4103/ijc.ijc_151_23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indian Journal of Cancer, 2025. Verfasst von Khalid Abdul Mannan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, Telangana, India. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, B7-H1 Antigen, Lung Neoplasms. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The Immune checkpoint inhibitors (ICI) targeting PDL-1 show improved outcomes in lung adenocarcinoma patients. This study is intended to understand the association of PDL-1 with molecular alterations in non small cell lung cancer patients.

Aims

To correlate clinicopathological features with molecular phenotype across PDL-1 subgroups and analyze survival outcomes for patients having PDL-1 expression (>1%). Materials and Methods: We did a retrospective study of 100 NSCLC cases diagnosed at primary and metastatic sites using a next-generation sequencing (NGS) lung panel and the PDL-1 SP263 clone on the Ventana platform. PDL-1 expression, sample size, sex, histological type, and oncogenic mutation status were analyzed. Patients with PDL-1 expression >1% and managed with immunotherapy (IO), targeted therapy (TT), and conventional chemotherapy (CC) were followed up for a median time of 7 months. The outcome was assessed as overall survival (OS).

Results

Fifty-one percent of the cases showed a positive PDL-1 expression. Squamous cell carcinoma (SCC) exhibited higher PDL-1 expression than adenocarcinoma (AC) ( P -value = 0.005). The KRAS expression was more frequent in males ( P -value = 0.048). There was no difference between the tumor location and the type of sample used. The EGFR mutation was exclusively seen in AC compared with other NSCLCs. The median overall survival in the IO and TT groups was 13 and 11 months, respectively, compared to 7 months in the CC group.

Conclusions

Integrating clinical, molecular, and immunological data will enhance the predictive value of PDL-1 biomarkers in lung adenocarcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungB7-H1 AntigenLung NeoplasmsHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAdultMutationBiomarkers, TumorPrognosisAged, 80 and over

Stichwörter der Autor:innen

Clinical outcomePDL-1molecular alterationnon-small cell lung cancer

Substanzen

B7-H1 AntigenCD274 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, Telangana, India.
  • Department of Medical Oncology, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, Telangana, India.

ORCID-Profile: Sahithi S Arya

Zitieren

APA

Mannan, K. A., Fonseca, D., Arya, S. S., Vaishnavi, K., Kodandapani, S., & Rajappa, S. J. (2025). PDL-1 in non-small cell lung cancer (NSCLC): Association with molecular alterations and clinical outcome. Indian Journal of Cancer. https://doi.org/10.4103/ijc.ijc_151_23

Vancouver

Mannan KA, Fonseca D, Arya SS, Vaishnavi K, Kodandapani S, Rajappa SJ. PDL-1 in non-small cell lung cancer (NSCLC): Association with molecular alterations and clinical outcome. Indian Journal of Cancer. 2025. doi:10.4103/ijc.ijc_151_23

BibTeX
@article{Mannan2025,
  author = {Mannan, Khalid Abdul and Fonseca, Daphne and Arya, Sahithi S and Vaishnavi, Kunteepuram and Kodandapani, Suseela and Rajappa, Senthil J},
  title = {PDL-1 in non-small cell lung cancer (NSCLC): Association with molecular alterations and clinical outcome},
  journal = {Indian Journal of Cancer},
  year = {2025},
  doi = {10.4103/ijc.ijc_151_23}
}
Kostenlos starten →